In its 2026 report, Health Canada presents regenerative medicine as a field capable of shifting therapeutic goals from symptom relief to restoring biological function in damaged cells, tissues, and organs.
The document, “2026 Watch List: Regenerative Medicine,” was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH) and published on April 22, 2026. It is an annual horizon scanning review that identifies five technology platforms and five related issues poised to significantly impact Canada’s health system over the next five years. The list was developed with input from 20 experts across various disciplines, including a patient partner, as well as literature reviews, industry reports, and a modified James Lind Priority Setting workshop.
According to the source, regenerative medicine builds on advances in gene editing, stem cell therapy, tissue engineering, and other approaches. Canada has made significant contributions to the field, but many technologies, even those developed domestically, are not yet readily accessible within the national healthcare system. The report emphasizes the need to identify barriers throughout the product lifecycle, from research to implementation.
The list of platforms and issues highlights practical examples, including specific technologies, clinical trials, and initiatives. These examples serve as illustrations rather than exhaustive lists and do not imply endorsement by the agency. The goal is to help decision-makers prepare proactively for the systemic changes required to realize the potential benefits of regenerative medicine for patients, clinicians, and the system as a whole.
The source notes that early identification of such platforms and issues allows for the shaping of policies, infrastructure, and regulatory approaches before widespread adoption. The report underscores the multidisciplinary nature of the field, where success depends on coordination among researchers, clinicians, regulators, patients, and funding systems.
According to CADTH, the focus on regenerative medicine in the 2026 Watch List is intended to support foresight and facilitate the translation of potential benefits into real-world clinical practice.
